Among the 10 patients for which biopsies were available, there was a trend toward an inverse correlation between the magnitude of decline in GR activation signaling in the tumor during cycle 2 and the time the patient spent on study (Fig. 3F; Pearson correlation −0.42; P value 0.23), suggesting a possible association between the degree of clinical benefit from the therapeutic regimen with the degree of tumor GR pathway inhibition. This evidence concerns the gene NR3C1 and neoplasm.